Hāʻawi ʻia i ka lāʻau lapaʻau no nā halemai maʻi maʻi maʻi

ʻO ka lawe ʻana i ka lāʻau lapaʻau i manaʻo ʻia no nā halemai maʻi maʻi: hoʻonui i ka maikaʻi o ka mālama ʻana i nā ʻōnaehana hoʻopuka lāʻau i hoʻololi ʻia i ka mālama ʻana i ka maʻi kanesa, e hāʻawi ana i ka maikaʻi maikaʻi a me ka hōʻemi ʻana i nā hopena ʻaoʻao no nā maʻi. Ke ʻimi nei kēia ʻatikala i nā ala like ʻole i hoʻohana ʻia ma ka hāʻawi ʻana i ka lāʻau lapaʻau no nā haukapila maʻi maʻi, e nānā ana i kā lākou mau hana, nā pono, a me nā pilikia. E ʻimi mākou i nā hiʻohiʻona kikoʻī a noʻonoʻo i ka wā e hiki mai ana o kēia kahua koʻikoʻi i ka oncology.

Ka hoomaopopo ana i ka hoopuka ana i na laau lapaau

He aha ka hoʻouna ʻana i ka lāʻau lapaʻau?

ʻAʻole like me ka chemotherapy kuʻuna, ka mea e hāʻawi i nā lāʻau lapaʻau a puni ke kino, ka hāʻawi ʻana i ka lāʻau lapaʻau no nā haukapila maʻi maʻi e kālele ana i ka hāʻawi pololei ʻana i nā mea lapaʻau i nā maʻi kanesa. Hoʻemi kēia ala i ka pōʻino i nā ʻiʻo olakino, e alakaʻi ana i ka liʻiliʻi o nā hopena ʻaoʻao a hoʻomaikaʻi i nā hopena lapaʻau. Hoʻohana ʻia nā ʻano hana like ʻole no ka hoʻokō ʻana i kēia hāʻawi i manaʻo ʻia, kēlā me kēia me nā hiʻohiʻona kūʻokoʻa a me nā noi.

Mechanisms of Targeted Drug Delivery

He mau mīkini maʻalahi ka hāʻawi ʻana i ka lāʻau lapaʻau no nā haukapila maʻi maʻi. Aia kēia mau mea:

• Nā mea hoʻohui lāʻau antibody (ADCs): Hoʻopili pono nā antibody i nā pūnaeau maʻi kanesa, e lawe pololei ana i ka lāʻau i hoʻopili ʻia i ka ʻōpū.
• ʻO ka lawe ʻana i ka lāʻau liposomal: Hoʻopili ʻia nā lāʻau lapaʻau i loko o nā liposomes, a laila kuhikuhi ʻia i nā maʻi maʻi maʻi me ka hoʻohana ʻana i nā ligand a i ʻole antibodies.
• Hāʻawi ʻia ka lāʻau lapaʻau Nanoparticle: Hiki ke hoʻolālā ʻia nā nanoparticles no ka lawe ʻana i nā lāʻau lapaʻau i ke kahua maʻi maʻi, hiki ke hoʻohana i ka hopena hoʻonui i ka permeability a me ka hoʻopaʻa ʻana (EPR).
• Nā nanoparticles i manaʻo ʻia: Hoʻohana kēia i nā hoʻololi o ka ʻili e like me nā ligands a i ʻole nā antibodies no ka huli pono ʻana i nā cell tumor.

Nā ʻano o nā ʻōnaehana lawe lāʻau i manaʻo ʻia

ʻO nā mea hoʻohui lāʻau antibody (ADC)

He laʻana koʻikoʻi nā ADC ka hāʻawi ʻana i ka lāʻau lapaʻau no nā haukapila maʻi maʻi. Hoʻohui lākou i ka kikoʻī o nā antibodies monoclonal me ka ikaika o nā lāʻau cytotoxic. Hoʻonui kēia ala i ka pono ma ka hāʻawi pololei ʻana i ka lāʻau lapaʻau i nā maʻi maʻi maʻi, ʻoiai e mālama ana i nā ʻiʻo olakino. No ka laʻana, trastuzumab emtansine (Kadcyla) he ADC i hoʻohana ʻia e mālama i ka maʻi maʻi umauma HER2 maikaʻi.¹

Hāʻawi ʻia i ka lāʻau lapaʻau Liposomal

Hoʻopili nā liposome i ka lāʻau lapaʻau, pale iā ia mai ka hoʻohaʻahaʻa ʻana a hoʻonui i kona manawa kaʻa i ke kahe koko. ʻO kēia pharmacokinetics i hoʻomaikaʻi ʻia e ʻae i ka lawe ʻia ʻana i nā cell tumor ma o nā ligands targeting kikoʻī a i ʻole ka hōʻiliʻili passive ma o ka hopena EPR. ʻO Doxorubicin liposomes (e laʻa, Doxil) he laʻana i ʻae ʻia.²

Nā Pōmaikaʻi a me nā Paʻakikī o ka Hoʻouna ʻana i ka Laʻau Laʻau

ʻO ka wā e hiki mai ana o ka lawe ʻana i ka lāʻau lapaʻau no nā halemai maʻi maʻi maʻi

Ke hoʻomau nei ka noiʻi e hoʻomaʻemaʻe a hoʻonui i nā hiki o ka hāʻawi ʻana i ka lāʻau lapaʻau no nā haukapila maʻi maʻi. Ke alakaʻi nei nā holomua i ka nanotechnology, genomics, a me imaging i ka hoʻomohala ʻana i nā ʻōnaehana ʻoi aku ka maʻalahi a me ka maikaʻi. ʻO ka hoʻohui ʻana o nā lāʻau lapaʻau pilikino a me ka hoʻohana ʻana i nā lāʻau lapaʻau hui pū kekahi e hoʻolaʻa i ke ala no ka hoʻomaikaʻi ʻana i nā hopena i ka mālama ʻana i ka maʻi kanesa. No ka 'ike hou aku e pili ana i ka ma'i ma'i 'a'ai a me ka noi'i, e kipa i ka Shandong Baofa Cancer Research Institute.

¹ FDA. (n.d.). Kadcyla (trastuzumab emtansine). Ua kiʻi ʻia mai [https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm361642.htm](https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm361642.htm)

² FDA. (n.d.). DOXIL (doxorubicin HCl liposomal injection). Lawe ʻia mai [https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020515](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=)020